EdiGene

EdiGene is a biotech company in Beijing, China, founded in 2016. It has raised $129.0M across 2 rounds, most recently a $62.0M Series B in April 2021.

博雅辑因 | 辑生命之密码 解世间之顽疾

Headquarters
Beijing
Founded
2016
Business Model
B2B
Total Funding
$129.0M
Last Round
$62.0M Series BApr 2021
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 10 investors for this company. The full record is or through the API.

About

EdiGene develops genome-editing technologies and translates them into cell and gene therapies for genetic diseases and cancer. Its research and development platforms include LEAPER for in vivo RNA base editing, MAGIC for immune-compatible cell therapies, targeted-therapy high-throughput genomic-editing screening, and bioinformatics capabilities. The company develops ex vivo, in vivo, and targeted therapeutic programs and states that it is focused on converting frontier gene-editing science into innovative therapies.

Summary

It has raised $129.0M in total across 2 rounds, most recently a $62.0M Series B round in Apr 2021. Investors include 3H Health, Loyal Valley Capital and IDG Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries B PlusApr 2021
$62.0M

Sign up to see all 2 events

Funding: Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

EdiGene on Indexed.vc
<a href="https://indexed.vc/companies/edigene"><img src="https://indexed.vc/api/badge/company/edigene" alt="EdiGene on Indexed.vc" width="260" height="76" /></a>